comparemela.com

கோஸ் குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

【财富周报】35家券商投资能力榜出炉,资管Nippon Wealth将结束香港服务

【财富周报】35家券商投资能力榜出炉,资管Nippon Wealth将结束香港服务
sina.com.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.cn Daily Mail and Mail on Sunday newspapers.

Germany s advise on avoiding AstraZeneca vaccine for those over 65 years could be counterproductive

Representational image. | Bulent Kilic / AFP Last week, a German vaccine advisory committee recommended the AstraZeneca vaccine only be used in 18-year to 64-year-olds, citing a lack of data on the efficacy of the vaccine in people over 65 years. Subsequently, the European regulator, the European Medicines Agency, conditionally approved the vaccine for anyone over 18. What can we make of this? Should we be giving this vaccine to older people or not? While we do not yet have all the data we would like, we do not have reason to believe this vaccine will not be at least somewhat effective in older adults. To exclude them from receiving it would not necessarily be the right approach.

Countries threaten to sue as EU Covid vaccine woes increase

Photo: Verwendung weltweit/ AFP The European Commission said it was trying to obtain more information. This comes on top of a halt to vaccinations in some parts of Europe due to a cut in deliveries of the Pfizer-BioNTech vaccine. AstraZeneca, which developed its vaccine with Oxford University, disclosed the situation in a statement, but gave few details. Initial volumes will be lower than originally anticipated due to reduced yields at a manufacturing site within our European supply chain, it said. Reuters news agency quotes an unnamed EU official as saying that the company had told the EU that the supply would reduce to 31 million - a cut of 60 percent - the number of doses it could deliver to the bloc in the first quarter of this year.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.